Sign in
Not yet recruitingPhase 3

Phosphate-Containing Replacement Fluid for Patients Undergoing CRRT

Key facts

Who runs it
Sun Yat-sen University
Where
China15 sites in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 3
People taking part
220 people, planned
Started
1 May 2026
Expected to end
30 Jun 2028
Type of study
Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • Phosphate-containing Replacement Fluid
  • Standard Phosphate-free Replacement Fluid
Record updated
24 April 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Participants must meet all of the following criteria to be eligible for the study:; Aged 18 years or older, regardless of gender; Meet the clinical indications for Continuous Renal Replacement Therapy (CRRT) as defined by the "Standard Operating Procedures for Blood Purification (2021 Edition)" and assessed by a qualified nephrologist or intensive care physician; Expected continuous blood purification duration is 72 hours or longer; The participant or their legal guardian has a full understanding of the purpose and significance of the trial, voluntarily agrees to participate and comply with the study procedures, and has signed the written Informed Consent Form (ICF)

Who cannot take part

  • Participants meeting any of the following criteria will be excluded from the study:; Known allergy to any component of the investigational drug, or individuals with an allergic constitution; Inability to establish suitable vascular access for CRRT; Persistent hypotension (Systolic Blood Pressure < 90 mmHg or Mean Arterial Pressure < 65 mmHg) that is difficult to correct, unless judged by the investigator as potentially correctable with intervention; Presence of malignant tumors with systemic metastasis (except for those who previously underwent radical surgery without recurrence); Pregnant or breastfeeding women; Receipt of any form of renal replacement therapy (RRT) or blood purification treatment within 24 hours prior to screening; Receipt of peritoneal dialysis within 24 hours prior to screening; Participation in any other clinical trial involving investigational drugs or devices within 1 month prior to screening; Any other condition or reason that, in the opinion of the investigator, makes the patient unsuitable for participation in the study

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Brief Summary: Evaluating a New Phosphate-Containing Fluid for Blood Purification (CRRT) Why is this study being done? Patients in the Intensive Care Unit (ICU) often need a treatment called Continuous Renal Replacement Therapy (CRRT). This is a type of blood purification that acts like an artificial kidney to clear toxins and extra fluid from the body.

Read full original descriptionShow less

A common problem during this treatment is that vital minerals, like phosphate, are washed out of the blood along with the toxins. Low phosphate can lead to muscle weakness and breathing problems. Currently, doctors must manually add phosphate to the treatment fluids, which can be inconsistent. This study aims to test a new, pre-mixed fluid that already contains phosphate to see if it works better and is safe.

What are the main questions the study aims to answer?

Does the new fluid help keep phosphate at a healthy level in the blood during the first 72 hours of treatment?

How does the new fluid affect kidney function compared to the standard fluid?

Is the new fluid safe for patients to use?

Who can take part in this study?

The study is looking for adults (18 and older) who:

Are in the ICU and need CRRT treatment as decided by their doctor.

Are expected to need this treatment for at least 72 hours.

Are willing to participate (or have a legal guardian who agrees).

People who are pregnant, have known allergies to the fluid ingredients, or have very low blood pressure that cannot be corrected may not be able to join.

How will the research happen? This is a "double-blind" study involving 220 participants across 15 hospitals. This means neither the patients nor the doctors will know which fluid is being used until the study is over.

Participants will be put into one of two groups by a computer:

Group 1 (New Fluid): Receives the blood purification fluid that has phosphate already in it.

Group 2 (Standard Fluid): Receives the standard fluid that does not have phosphate.

What will participants have to do?

Receive Treatment: Participants will receive their assigned fluid during their normal CRRT care for up to 7 days.

Blood Tests: Doctors will take regular blood samples to check mineral levels and kidney health.

Monitoring: The medical team will closely watch participants for any side effects or safety concerns.

Follow-up: There will be a safety check-up 7 days after the treatment ends.

Possible Benefits and Risks The new fluid may help prevent low phosphate levels, which could help with recovery. However, as with any medical treatment, there is a risk of side effects or electrolyte imbalances. The research team will monitor every participant 24/7 to ensure their safety.

The 2 groups in the trial

  • Experimental Group: Phosphate-containing Replacement FluidTreatment being tested

    Participants in this arm will receive the phosphate-containing replacement fluid during Continuous Renal Replacement Therapy (CRRT). The solution is a premixed, electrolyte-balanced fluid containing phosphorus (as phosphate ions). Administration: Delivered via the replacement fluid port of the CRRT machine. Dose/Flow Rate: Standardized according to the study protocol (e.g., 25-35 mL/kg/h) to maintain hemodynamic stability and solute clearance. Duration: Expected intervention duration is 72 hours, with a maximum treatment period of up to 7 days, or until clinical termination of CRRT.

    Treatment: Phosphate-containing Replacement Fluid

  • Control Group: Standard Phosphate-free Replacement FluidSham treatment, for comparison

    Participants in this arm will receive a standard phosphate-free replacement fluid (Basal replacement solution) during Continuous Renal Replacement Therapy (CRRT). This solution contains standard electrolytes (Sodium, Potassium, Calcium, Magnesium, Chloride) and bicarbonate but lacks phosphate. Administration: Delivered via the replacement fluid port using the same CRRT equipment and settings as the experimental group. Dose/Flow Rate: Managed identically to the experimental group to ensure a comparable dialysis dose. Duration: Expected intervention duration is 72 hours, with a maximum treatment period of up to 7 days, or until clinical termination of CRRT.

    Treatment: Standard Phosphate-free Replacement Fluid

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-Blind, Parallel-Controlled, Multicenter, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Phosphate-Containing Replacement Fluid in Continuous Renal Replacement Therapy
Record updated
24 April 2026